RAPT Therapeutics (FRA:0RA) Debt-to-Asset : 0.05 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics Debt-to-Asset?

RAPT Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €2.39 Mil. RAPT Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €2.94 Mil. RAPT Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €118.15 Mil. RAPT Therapeutics's debt to asset for the quarter that ended in Jun. 2024 was 0.05.

RAPT Therapeutics Debt-to-Asset Historical Data

The historical data trend for RAPT Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics Debt-to-Asset Chart

RAPT Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.04

RAPT Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.05

Competitive Comparison of RAPT Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, RAPT Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RAPT Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's Debt-to-Asset falls into.

RAPT Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

RAPT Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.245	+	4.088)	/	158.943
	=	0.04

RAPT Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.386	+	2.935)	/	118.15
	=	0.05

RAPT Therapeutics (FRA:0RA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

RAPT Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

RAPT Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (FRA:0RA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RAPT:USA

Address

561 Eccles Avenue, South San Francisco, CA, USA, 94080

Website

https://www.rapt.com

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Headlines

No Headlines